

## *Curriculum Vitae*

### **Prof Frances M. Boyle AM**

#### **Medical Oncologist**

MBBS (Hons I), UQLD Dec 1984, University Medalist

FRACP (Medical Oncology) 1992

PhD (Pharmacology) USyd 1999

<i>The Patricia Ritchie Centre for Cancer Care and Research</i> Mater Hospital 25 Rocklands Rd North Sydney NSW 2060 Australia Phone +61-2-99007300 Fax +61-2-99540536 E-Mail <a href="mailto:frances.boyle@sydney.edu.au">frances.boyle@sydney.edu.au</a>	<i>Consulting Rooms</i> Suite 7, Level 3, The Poche Centre 40 Rocklands Rd North Sydney NSW 2060 Australia Phone +61-2-99577744 Fax +61-2-99540808 Email <a href="mailto:franb@bigpond.net.au">franb@bigpond.net.au</a>
---	---

#### **Current roles:**

- Sydney Medical School: Professor of Medical Oncology, Northern Clinical School.
- The Patricia Ritchie Centre for Cancer Care and Research, The Mater Hospital North Sydney: Director.
- Royal North Shore Hospital, Sydney: Honorary Medical Officer.
- North Shore Private Hospital, Sydney: Consulting Medical Oncologist,
- Melanoma Institute of Australia: Medical Oncologist.
- Sydney Vital Translational Cancer Research Centre, Executive Member
- Pam McLean Communications Centre, University of Sydney: Medical Director.
- ANZ Breast Cancer Trials Group: Chair, Board of Directors.
- ANZ Breast Cancer Trials Group: Member, Scientific Advisory Committee.
- Medical Oncology Group of Australia: Member of Education Subcommittee, Chair of Breast Cancer Interest Group, and Convenor, Communication skills programme.
- Mater Hospital Sydney: Member, Medical Advisory Committee.
- University of Newcastle: Conjoint Professor of Medical Oncology.
- International Breast Cancer Study Group: Board Member and SAC Member

#### **Personal:**

Place of Birth: Brisbane, Australia.

Citizenship: Australian

**Academic Record:****Undergraduate Medical Education:**

Medical School: University of Queensland 1979 - 1984.

Distinctions: Awarded Bachelor of Medicine and Surgery (MBBS) 1984

First Class Honours.

University Medal 1984.

RACGP prize for Community Medicine 1983.

**Postgraduate Clinical Training**

1985/86: Intern, RMO, Mater Misericordiae Public Hospitals, Brisbane.

1987/88/89: Basic Physician Training, Mater Misericordiae Adult Hospital, Brisbane.

1990/91 Advanced Training in Medical Oncology,  
Royal North Shore Hospital, Sydney and associated clinics.

1992: Senior Medical Registrar, Royal North Shore Hospital.

Awarded Fellowship Royal Australasian College of Physicians December 1992  
(Medical Oncology)

*Registered as a Consultant Physician / Medical Oncologist MED 0001152470*

**Previous clinical Appointments as a consultant medical oncologist:**

- Visiting Medical Oncologist, Northern Rivers AHS, 1995-2000.
  - Lismore Outreach Medical Oncologist service from RNSH weekly
- Staff Specialist, Royal North Shore Hospital, Sydney, 1995-2006.
  - Part time clinical appointment and Breast Cancer MDT Coordinator
  - Conjoint Lecturer / Senior Lecturer Northern Clinical School

**Research Training*****PhD 1999 University of Sydney ( Pharmacology) and Post Doc training.***

My PhD project involved the development of animal models in which to study nerve injury induced by cytotoxics, and evaluated the amino-acid glutamate as a neuroprotectant. This work was funded by an NHMRC Scholarship 1993-96. It was supervised by Prof Gillian Shenfield and attracted grant funding from the NSW Cancer Council and National Breast Cancer Foundation. It was carried out in the Bill Walsh Laboratories at RNSH. Awards during PhD included the Beryl and Jack Jacobs and Glaxo Travel Awards. Results were presented at AACR and published in Journal of Pharmacology and Experimental Therapeutics (JPET) and Neuro-oncology. In post-doctoral work the models were extended to other cytotoxics and the neuroprotectant Leukaemia Inhibitory Factor, published in JPET, and tested in a clinical trial. Techniques for clinical measurement of neuropathy learnt at Johns Hopkins Hospital were used in a study of thalidomide in patients with brain tumours.

**Current Clinical Trials Research.**

I have been involved in recruiting patients to breast cancer clinical trials of the ANZBCTG for 14 years, and become a Board Member 12 years ago, assisting with development of the research agenda and protocol planning through the Scientific Advisory Committee (SAC). In 2012 I was elected Chair of the Board. I chaired the SAC from 2005-10 and interacted with international trials groups to set the agenda for Australian and NZ participation in international cooperative groups trials as well as supporting investigator initiated studies in ANZ. I have convened Annual Scientific Meetings 2005-13 for the ANZ BCTG.

At the Mater I have initiated the Clinical Trials Programme through the Patricia Ritchie Centre for Cancer Care and Research. As Director, I have employed and trained research staff and administered budgets, ethics and governance applications. I am Mater Principal Investigator on the following current multicentre phase 3 trials in Breast Cancer

- Aromatase inhibitors as early and late adjuvant therapy in breast cancer (FACE, LATER\* and SOLE)
- Suppression of ovarian function (SOFT) and Cognitive substudies\*, and POEMS
- IBIS 2 prevention study in DCIS and Decision aid study\*
- Late adjuvant Lapatinib (TEACH)\*
- Her2 positive adjuvant trials ALTTO (Lapatinib)\* and Aphinity (Pertuzumab).
- First line trials in metastatic breast cancer with the PI3kinase inhibitor BKM120 (Belle 2 and 4).

*\*Member of steering or executive committees managing these trials*

I am currently Principal Investigator on the following supportive care trials recruiting patients at the Mater, and am involved in trial development and management:

- Survivorship care planning in Breast Cancer with Meagan Brennan (PhD student) and Phyllis Butow (CEMPED U Syd).
- Cognitive Rehabilitation (“Brain train”) and preventive interventions (Ginkgo Biloba) in women receiving chemotherapy for breast cancer with J Vardy and H Dhillon (CEMPED, U Syd)
- Evaluation of scalp cooling for prevention of chemotherapy induced alopecia with Lina Pugliano (POCOG).
- Evaluation of EORTC Quality of life instruments for Melanoma, Spritual well-being and chemotherapy induced alopecia with Julie Winstanley (U Syd).
- Evaluation of Cancer Pain guidelines and a clinical management pathway for patients with advanced cancer pain with Melanie Lovell (Impact and POCOG).
- Development and Evaluation of a Decision Aid for patients contemplating neoadjuvant chemotherapy for Breast Cancer with Nicholas Zdenkowski (PhD Student and ANZ BCTG).
- Development of support groups for patients with Stage 3 melanoma with Melanoma Institute Australia and Cancer Council NSW.
- Assessment of linguistic aspects of communication with patients with melanoma, in relation to socioeconomic status, with Melanoma Institute Australia and Prof Geoff Williams.

***Research Funding.*****CURRENT GRANT FUNDING AS CI**

<b>NSW Cancer Institute 2014-18</b>	<b>\$4,865,770</b>
<b>Northern Translational Cancer Research Centre</b>	
A Engel, D Bailey, F Boyle, S Clarke, A Gill, D Marsh, M Molloy. Kolling Institute (University of Sydney.)	
<b>NHMRC Project Grant 1080521 2015-19</b>	<b>\$818,440</b>
“Long Term Nerve Damage in Cancer Survivors” S Park, D Goldstein, F Boyle et al (University of NSW)	
<b>Cancer Council NSW NT 14-008 2015-16</b>	<b>\$360,000</b>
“Breast Cancer Therapies that target IGF BP3 signaling” R Baxter, F Boyle, J Martin. Kolling Institute (University of Sydney)	
<b>Ophthalmic Research Institute of Australia (ORIA) 2015</b>	<b>\$27,000</b>
Aromatase inhibitor therapy for breast cancer and dry eye. S Watson, F Boyle, H Inglis, M Friedlander. Save Sight Institute (University of Sydney)	
<b>ANZ Breast Cancer Trials Group 2015-16</b>	<b>\$49,000</b>
Madarosis in patients undergoing chemotherapy for breast cancer. Y Antill, K Morris, F Boyle Cabrini and Mater Hospitals.	
<b>NBCF Accelerator Grant 2014-17.</b>	<b>\$939,139</b>
Implementing a national clinical pathway for pain to ensure equitable, cost effective, evidence based, person-centred care for people with advanced breast cancer. M Lovell, J Phillips, M Agar, F Boyle et al. (University of Sydney)	
<b>NHMRC Eliminate: A Randomised phase II trial of neoadjuvant chemotherapy +/- concomitant aromatase inhibitor endocrine therapy to downstage larger ER positive breast cancer. 2014-18</b>	<b>\$2,182,283</b>
P Francis, F Boyle, J Forbes, N Wilcken. ANZ Breast Cancer Trials Group (University of Newcastle)	
<b>Big Data Big Impact Grant NSW Cancer Institute 2014</b>	<b>\$60,000</b>
“The impact of hypoglycemic agent use on early breast cancer outcomes: an analysis of SEER-Medicare clinical data and the biological rationale” L Pugliano, R Baxter, S Lord, F Boyle, S Twigg, J Winstanley, M Stockler. Patricia Ritchie Centre, Mater Hospital (University of Sydney)	
<b>HCF Research Foundation 2014-15</b>	<b>\$190,936</b>
Evaluation of a Decision Aid for women considering neoadjuvant systemic therapy for operable breast cancer N Zdenkowski, F Boyle, P Butow, B Mann, J Forbes, L Reaby, V Gebiski, N Wilcken ANZ Breast Cancer Trials Group (University of Newcastle)	

**NHMRC Partnership Project 1074356 2014-18** **\$1,267,110**  
 Healthy Living after Cancer  
 E Eakin, S Hayes, M Haas, M Reeves, J Vardy, F Boyle et al  
 (University of QLD.)

**ARC Linkage Grant LP130100441 2013-16** **\$407,000**  
 Rekindle – Sexuality after cancer. Development and testing of a novel web based psychoeducational resource for both survivors and their partners.  
 C Lawsin, P Butow, I Juraskova, S Lambert, J Kay, K McGeechan, F Boyle  
 University of Sydney and NSW Cancer Council

**The Friends of the Mater Foundation 2014-15** **\$29,490**  
 Effects of Melanoma Patients SES on Communication.  
 F Boyle, G Williams, J Thompson. Melanoma Institute of Australia.

**The Friends of the Mater Foundation 2014-16** **\$49,379**  
 Development and Evaluation of support groups for Stage 3 Melanoma Patients.  
 F Boyle, A O'Reilly. Patricia Ritchie Centre, Mater Hospital.

**Priority Driven Collaborative Cancer Research Scheme 2012-15** **\$600,000**  
**“Ginkgo Biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind placebo controlled randomized phase III trial.**  
 J Vardy, H Dhillon, M Bell, M Tattersall, Lysique, F Boyle, S Clarke. CEMPED  
 (University of Sydney.)

**NHMRC ID 510787 2008-15** **\$4,430,875**  
**“Prevention of Later breast cancer events in postmenopausal women with endocrine responsive breast cancer.**  
 J Forbes, A Coates, F Boyle, M Green, R Snyder, J Cuzick.  
 ANZ Breast Cancer Trials Group (University of Newcastle).

**PREVIOUS GRANT FUNDING as CI/AI.**

**The Friends of the Mater Foundation. 2013-14** **\$20,000**  
**“Development of a Quality of Life instrument to evaluate chemotherapy induced alopecia.”**  
 J Winstanley, F Boyle. Patricia Ritchie Centre and EORTC. (University of Sydney)

**The Friends of the Mater Foundation 2010-14** **\$52,000**  
**“Evaluation of scalp cooling for prevention of chemotherapy induced alopecia, including pharmacogenomics and pharmacokinetics”**  
 K Andrews, F Boyle, J Winstanley, L Pugliano. Patricia Ritchie Centre, Mater.

**Cancer Australia 2012-14** **\$466,498**  
**“Endocrine therapies for early breast cancer: health outcomes and policy implications in Australian Clinical Practice”**  
 D Preen, L Roughead, C Saunders, A Kemp, M Bulsara, CDJ Holman, F Boyle.  
 (University of WA).

**European Organisation for Research & Treatment of Cancer 2011-14 \$130,000**  
**“International study to develop a Quality of Life module for patients with melanoma.”**

J Winstanley, M King, J Thompson, F Boyle. MIA (University of Sydney).

**NHMRC ID 569213 2009-13 \$1,635,000**  
**“A randomised phase 3 trial of anastrozole for breast cancer prevention in postmenopausal women at high risk”**

J Forbes, A Coates, F Boyle, B Mann, C Saunders, J Cuzick  
 ANZ Breast Cancer Trials Group (University of Newcastle).

**NSW Cancer Institute Translational Research Unit 2011-13 \$1,600,000**  
**Northern Translational Cancer Research Unit**

S Clarke, B Robinson, D Marsh, R Baxter, A Gill, F Boyle. Kolling Institute  
 (University of Sydney.)

**National Breast Cancer Foundation Novel Concept Award 2012 \$200,000**  
**“Breast Cancer in pregnancy: Surveillance, Management, Outcomes and Experiences.”**

E Sullivan, C Saunders, J Dickinson, F Boyle, A Ives, L Halliday, N Rose-Humphreys. (University of NSW)

**National Breast Cancer Foundation Think Tank Grants 2012 \$20,000**  
**“National tissue bank of matched primary breast cancer and metastases obtained at autopsy.”**

R Anderson, B Chua, C Saunders, S Lakhani, F Boyle. (University of WA).

**Friends of the Mater Foundation 2008-12 \$87,724**  
**“Survivorship Care planning in early breast cancer.”**

M Brennan, A Spillane, P Butow, F Boyle.  
 University of Sydney PhD project. Patricia Ritchie Centre, Mater Hospital.

**NHMRC ID632558 2010-12 \$397,125**  
**“Protein discovery for breast cancer diagnosis”**

R Baxter, D Marsh, N McCarthy, F Boyle, K Moore, L Chung.  
 Kolling Institute (University of Sydney).

**NHMRC ID 454507 2007-11 \$285,950**  
**“Cognitive effects of adding ovarian function suppression to adjuvant hormonal therapy in premenopausal breast cancer.”**

K-A Phillips, P Francis, F Boyle, J Bernhard, P Maruf.  
 ANZ Breast Cancer Trials Group and Peter McCallum Cancer Institute (Uni Melb).

**The Friends of the Mater Foundation 2010-11 \$20,000**  
**“Brain Train” – cognitive rehabilitation for breast cancer survivors”**

J Vardy, H Dhillon, F Boyle. Patricia Ritchie Centre, Mater Hospital.

**The Friends of the Mater Foundation 2010-11** **\$20,000****“A randomized trial of Ginkgo Biloba in prevention of chemotherapy induced cognitive dysfunction in early breast cancer”**

J Vardy, V Bray, F Boyle. Patricia Ritchie Centre, Mater Hospital.

**NHMRC ID 510788 2008-10** **\$287,000****“Targeted endocrine therapy for young women with breast cancer.”**J Forbes, A Coates, F Boyle, J Chirgwin, P Francis, R Snyder.  
ANZ Breast Cancer Trials Group (University of Newcastle).**Australian Health Research Institute 2009-10** **\$153,000****“Optimising recovery from breast cancer treatment: the ORBT study.”**

M Cousins, F Blyth, F Boyle. Pain Management and Research Centre (University of Sydney) and Patricia Ritchie Centre, Mater Hospital.

**The Friends of the Mater Foundation 2009-11** **\$17,600****“Development of a psychoeducational program for patients with high risk melanoma: assessing patient needs and clinician communication strategies.”**

F Boyle, P Butow, A O'Reilly, R Saw, J Tan.

Patricia Ritchie Centre and Melanoma Institute of Australia, Masters Psychology University of Sydney.

**NHMRC ID 455513 2007-9** **\$387,400****“A clinical trial evaluating neoadjuvant chemotherapy for women with large operable or locally advanced breast cancer.”**J Forbes, A Coates, M Friedlander, N McCarthy, F Boyle, M Green.  
ANZ Breast Cancer Trials Group (University of Newcastle)**Cancer Institute NSW Multidisciplinary Research 2007-8** **\$140,000****“Enhancing multidisciplinary care across the public-private interface”**

F Boyle, K Moore, K Andrews

Patricia Ritchie Centre and RNSH Breast Cancer Care Centre

**Friends of the Mater Foundation 2007-8** **\$30,000****“Current communication issues in oncology”**

F Boyle, P Butow, S Dunn, J Shaw. Patricia Ritchie Centre.

USyd Medical student honours projects (S Tolerton, E Kaser, K Wesling) in association with the Pam McLean Centre.

**Friends of the Mater Foundation 2007-9** **\$40,000****“Proteomics in breast cancer”**

K Moore, F Boyle, S Shibli, R Baxter. Patricia Ritchie Centre.

Masters of Surgery student project S Shibli in association with the Kolling Institute.

**National Breast Cancer Foundation** **\$100,000****“Communicating with patients from Chinese and Arabic backgrounds about disease recurrence”.**

P Butow, D Goldstein, M Sze, F Boyle. POCOG (University of Sydney).

- Australian Health Research Institute 2008-9** **\$100,000**  
**“Exploring the epidemiology and mechanisms of breast cancer surgical pain.”**  
M Cousins, F Blyth, F Boyle.  
Pain Management and Research Centre (University of Sydney).
- NHMRC 351161. 2005-7** **\$300,000**  
**“Targeted endocrine therapy for young women with breast cancer.”**  
J Forbes, A Coates, F Boyle, P Francis, R Snyder.  
ANZ Breast Cancer Trials Group (University of Newcastle)
- Susan Komen Foundation (USA) 2005-7** **\$348,600.**  
**“A randomized controlled trial of a decision aid for women in IBIS- 2.”**  
P Butow, J Forbes, A Coates, F Boyle, N McCarthy, I Juraskova.  
University of Sydney and ANZ Breast Cancer Trials Group.
- Office for the Status of Women 2004** **\$50,000**  
**“Women talk cancer – multicultural communication in cancer”**  
With Aust Fed’n Medical Women and Pam McLean Centre, University of Sydney
- Telstra Foundation 2004-5** **\$80,000**  
**“Resources for children whose parents have cancer”**  
K Sundquist, A O Reilly, J Friedsam, S Dunn, F Boyle.  
NSW Cancer Council and Pam McLean Centre, University of Sydney
- NHMRC Strategic Palliative Care Research Grant 2004-5** **\$150,000**  
**“Discussing prognosis & end-of-life issues in palliative care; current practice & development of an evidence based training program.”**  
J Clayton, P Butow, M Tattersall, D Currow, K Clark, S Aranda, F Boyle
- NHMRC Evidence Based Clinical Practice Research 1999-2000** **\$80,000**  
**“Structural change to support guideline implementation”**  
S Redman, H Zorbas, K Luxford (NBCC)
- Andrew Olle Foundation for Neuroscience 2000-3** **\$90,000**  
**“Mechanism of Action of Thalidomide in the treatment of brain tumours.”**  
F Boyle, H Wheeler, S Murphy (PhD University of Sydney)
- Rural Health Support Education and Training Grant 2001-3** **\$120,000**  
**" Management of Adjuvant therapy for breast and colorectal cancer in rural areas"**  
D Goldstein, C Underhill, F Boyle (Medical Oncology Group of Australia)
- Northern Sydney Area Health Service Grant 1999-2000** **\$15,000**  
**“Cancer Pain Communication.”**  
F Boyle, S Dunn. (Pam McLean Centre, University of Sydney)
- Leo and Jenny Cancer and Leukaemia Foundation 1997** **\$7,750**  
**“Docetaxel and vinorelbine neuropathy models.”**  
F Boyle, H Wheeler. (Bill Walsh Labs, RNSH)
- Kathleen Cunningham Foundation for Breast Cancer Research 1996** **\$25,000**



for Cisplatin and Paclitaxel neuropathy studies.  
F Boyle, H Wheeler. (Bill Walsh Labs, RNSH)

**Northern Sydney Area Health Service 1994-95** **\$9,000**

Mechanisms of cytotoxic neuropathy.  
F Boyle, H Wheeler. (Bill Walsh Labs, RNSH)

**NSW Cancer Council 1995.** **\$7,750**

Glutamate as a neuroprotectant.  
F Boyle, H Wheeler. (Bill Walsh Labs, RNSH)

**Previous Industry Collaborative Funding**

**Glaxo Smith Kline 2009-11** **\$600,000**

**“Exploring the mechanisms of mucositis induced by targeted therapies for breast cancer”**

D Keefe, F Boyle, J Bowen.  
Adelaide Cancer Centre (University of Adelaide)

**AMRAD funding for LIF laborarory studies** **\$20,000**

Animal Model of neuropathy for testing LIF as a neuroprotectant.  
F Boyle, H Wheeler. (Bill Walsh Labs, RNSH)

**Clinical Trials Infrastructure Funding for Patricia Ritchie Centre, Mater**

**NSW Cancer Institute 2007-14** **\$200,000**

Data Manager support for investigator initiated academic trials

**The Friends of the Mater Foundation (Ritchie Family) 2007-14** **\$800,000**

Research Manager position salary for multicentre trials.

**Cancer Council NSW** **\$100,000**

Data Manager support annually 2003-2006

**Friends of the Mater Foundation (Ritchie Family Trust) 2003-2006** **\$400,000**

Clinical trials manager salary support and Margaret McGovern PhD Scholarship (Psycho-oncology) for Rhea Stein, University of Sydney.

**Clinical Trials Infrastructure for ANZ Breast Cancer Trials Group**

**NSW Cancer Institute NSW 2009 -11** **\$330,000**

J Forbes, S Ackland, F Boyle, A Coates (University of Newcastle)

**Cancer Australia Protocol Development infrastructure Grant 2013-15** **\$400,000**

F Boyle, J Forbes, S Smith

## **Publications**

### **Original Research / Creative Peer Reviewed Papers (Published/Accepted)**

1. Boyle FM, Georghiou PR, Tilse MH, McCormack JG. "Branhamella (moraxella) catarrhalis: pathogenic significance in respiratory infection." MJA 1991, 154:592-6. Impact factor 3.3
2. Boyle FM, Taylor KM, Bell JR. "Ovarian Follicular Non-Hodgkins Lymphoma." Pathology 1991, 23:164-166. Impact Factor 1.2
3. Boyle FM, Bell DR. " Breast Cancer Treatment outside teaching hospitals" ANZ J Med 1992, 22:309-310. Impact Factor 1.6
4. Boyle FM, Smith R, Levi JA. "Continuous hepatic artery infusion of 5FU for metastatic Colorectal Cancer." ANZ J Med, 1993, 23:32-34. Impact Factor 1.6
5. Shannon JA, Bell DR, Levi JA, Wheeler HR, Boyle FM. "Bone Presentation of Non-Hodgkins lymphoma." ANZ J Med, 1994, 24:701-704. Impact Factor 1.6
6. Boyle FM, Pendlebury SC, Bell DR. "Further insights into the natural history and management of cutaneous neuroendocrine (Merkel Cell) carcinoma." Int J Rad Onc Biol Phys, 1995,31:315-323. Impact Factor 4.8
7. Boyle FM, Wheeler HR, Shenfield GM. "Glutamate ameliorates experimental vincristine neuropathy." J Pharm Exp Ther, 1996,279:410-415. Impact Factor 4.07
8. Boyle FM, Wheeler HR, Shenfield GM. "Prevention of experimental cisplatin and paclitaxel neuropathy with glutamate." J Neuro-Oncology, 1999,41:107-116. Impact factor 2.9
9. Boyle FM, Beatson C, Monk R, Grant S, Kurek J. "The experimental neuroprotectant Leukaemia Inhibitory Factor (LIF) does not compromise cytotoxicity of paclitaxel, cisplatin and carboplatin." Cancer Chemotherapy and Pharmacology, 2001, 48:429-434. Impact factor 2.7
10. Marx GM, Pavlakis N, McCowatt S, Boyle F et al. "Phase II study of Thalidomide in the treatment of recurrent Glioblastoma Multiforme" J Neuro-oncology, 2001,54:31-8. Impact Factor 2.9
11. Henman MJ, Butow PN, Brown RF, Boyle FM, Tattersall MHN. "Lay constructions of decision-making in cancer". Psychooncology 2002, 11: 295-306. Impact Factor 2.8
12. Brown RF, Butow PN, Henman MJ, Dunn SM, Boyle FM, Tattersall MNH. "Responding to the active and passive patient: flexibility is the key." Health Expectations, 2002, 5:330-340. Impact Factor 2.3

13. Loh WP, Butow PN, Brown RF, Boyle F. "Ethical communication in clinical trials: Issues faced by data managers in obtaining informed consent." *Cancer* 2002, 95:2414-21. Impact Factor 4.9
14. Potter V, Wiseman E, Dunn S, Boyle FM. "Patient Barriers to optimal cancer pain control." *Psycho-oncology* 2003, 12:153-60. Impact Factor 2.8
15. Baron-Hay S, Boyle F, Ferrier A, Scott C. "Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer". *Clin Cancer Res* 2004, 10:1796-806. Impact Factor 6.75
16. Brown, RF, Butow PN, Boyle F, Tattersall MNH. "Seeking informed consent to cancer clinical trials:describing current practice". *Soc Sci Med* 2004, 58:2445-57. Impact Factor 2.7
17. Boyle FM, Robinson E, Heinrich P, Dunn SM. "Cancer: Communicating in the team game" *ANZ J Surg* 2004, 74: 477-481. Impact Factor 1.3
18. Brown RF, Butow PN, Sharrock M, Henman M, Boyle F, Goldstein D, Tattersall MNH. "Education and role modelling for clinical decisions with female cancer patients." *Health Expectations* 7:303-316, 2004. Impact Factor 2.3
19. Boyle F, Eller S, Grossman S. "Penetration of intraarterially administered vincristine in experimental brain tumor". *Neurooncology* 6: 300-5, 2004. Impact Factor 5.4
20. Boyle FM, Robinson E, Dunn SM, Heinrich P. "Multidisciplinary Care in Cancer: The fellowship of the ring." *Journal of Clinical Oncology*, 2005, 23: 916-920. Impact Factor 18.9
21. Thewes B, Meiser B, Duric VM, Stockler MR, Taylor A, Stuart-Harris R, Links M, Wilcken N, MacLachlan SA, Phillips KA, Beith J, Boyle F, Friedlander ML. "What survival benefits do patients with pre-menopausal early breast cancer need to make endocrine therapy worthwhile?" *Lancet Oncology*, 2005, 6: 581-588. Impact Factor 17.76
22. Duric V, Stockler MR, Heritier S, Boyle F, Beith J, Sullivan A, Wilcken N, Coates A, Simes RJ. "Patients' preferences for adjuvant chemotherapy in early breast cancer: What makes AC and CMF worthwhile now?" *Annals of Oncology*, 2005, Nov 16:1786-94. Impact Factor 6.4
23. Dalton L, Boyle F, Goldstein D, Underhill C, Yates P, Luxford K. "An Educational workshop program for rural practitioners to encourage best practice for delivery of systemic adjuvant therapy". *J Cancer Education*. 21:35-39, 2006. Impact Factor 0.6
24. Murphy-Poulton SF, Boyle F, Gu GX, Mather LE. "Thalidomide enantiomers: determination in biological samples by HPLC and vancomycin-CSP." *J Chromatography (B)*, 2006, 831:48-56. Impact Factor 4.06

25. Brown RF, Butow PN, Boyle F, Tattersall MHN. "Seeking informed consent to cancer clinical trials: evaluating the efficacy of doctor communication skills training." *Psychooncology* 2006 16;507-516. Impact Factor 2.8
26. Murphy S, Boyle F, Davey R, Gu XQ, Mather LE. Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. *J Pharm Pharmacol*, 2007, 59:105-114. Impact Factor 4.09
27. Murphy S, Davey RA, Gu XQ, Haywood M, McCann L, Mather L, Boyle F. "Enhancement of cisplatin efficacy by thalidomide in a 9L gliosarcoma model." *J Neurooncology*, 2007 85:181-9. Impact Factor 2.9
28. Duric VM, Stockler MR, Butow PN, Sharpe L, Heritier S, Beith J, Boyle F, Wilcken N, Coates AS, Simes RJ. "Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer". *Psychooncology* 2007, 16: 48-59. Impact Factor 2.8
29. Juraskova I, Butow P, Lopez A, Seccombe M, Boyle F, McCarthy N, Reaby L, Forbes JF. "Improving informed consent: A pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II)." *Health Expectations* 2008 11:252-262. Impact Factor 2.3
30. Crown JP, Burris HA, Boyle F et al. "Pooled Analysis of Diarrhea Events in Cancer patients Treated With Lapatinib." *Breast Cancer Research and Treatment*, E Pub Jan 20 2008. Impact Factor 5.7
31. Duric VM, Butow PN, Sharpe L, Heritier S, Boyle F, Beith J, Wilcken NR, Coates AS, Simes RJ, Stockler MR. "Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer". *Patient Education and Counselling*. 2008 72:239-245. Impact Factor 2.7
32. Schapira L, Brown R, Boyle FM, Butow P. "Pessimism is no poison" *J Clin Oncol* 2010;28:705-7. Impact Factor 18.9
33. Lovell MR, Forder P, Stockler M, Butow PN, Briganti, E, Chye R, Goldstein D, Boyle FM. "A randomised controlled trial of a standardised educational intervention for patients with cancer pain." *Journal of Pain and Symptom Management*. 2010;40:49-59. Impact Factor 2.4
34. Brennan M, Spillane A, Butow P, Boyle FM. "Survivorship care after breast cancer— Follow-up practices of Australian health professionals and attitudes to a survivorship care plan." *Asia Pacific Journal of Clinical Oncology*, 2010;6:116-25. Impact Factor 0.3
35. Kaser E, Shaw J, Marven M, Swinburne L, Boyle F. "Communication about high cost drugs in oncology – the patient view." *Annals of Oncology* 2010;21:1910-4. Impact Factor 6.4

36. Brennan M, Butow P, Marven M, Spillane AJ, Boyle FM. "Survivorship care after breast cancer treatment- Experiences and preferences of Australian women", *The Breast*, 2011;20:271-7. Impact Factor 2.5
37. Lee C, Stockler M, Ackland S, Gebiski V, Lord S, Friedlander M, Boyle FM, Simes J. "A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer" *Breast Cancer Research and Treatment*, 2011;129:467-76. Impact Factor 5.7
38. Tolerton S, Shaw J, O'Reilly A, Dunn S, Boyle FM. "Exploring Consent to randomized placebo-controlled clinical trials in oncology." *Asia Pacific Journal of Clinical Oncology*, 2011, 7:300-306. Impact factor 2.3
39. Goldstein D, Bennett BK, Webber K, Boyle F, DeSouza P, Wilcken N, Scott E, Toppler R, Murie P, O'Malley L, McCourt J, Friedlander M, Hickie I, Lloyd AR. Cancer-related fatigue in women with breast cancer: outcomes of a five year prospective cohort study. *JCO*, 2012, 30:1805-12. Impact Factor 18.9
40. Clayton J, P Butow, Waters A, Powell R, O'Brien A, Boyle F et al. Evaluation of a novel individualized communication-skills training intervention to improve doctors' confidence and skills in end-of-life communication. *Palliative Medicine*, June 18 2012 epub. Impact factor 2.383
41. Cameron B, Bennett B, Boyle F et al. Post-cancer fatigue is not associated with immune activation or altered cytokine production. *Annals Oncology*. 2012, 23:2890-5. Impact Factor 6.425.
43. Luckett T, Davidson PM, Green A, Boyle F et al. Assessment and Management of Adult Cancer Pain: A Systematic Review and Synthesis of Recent Qualitative Studies Aimed at Developing Insights for Managing Barriers and Optimizing Facilitators Within a Comprehensive Framework of Patient Care. *J Pain Symptom Management*. 2013;45:229-53. Impact factor 2.6.
43. Bowen JM, Mayo BJ, ...Boyle FM et al. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. *Cancer Biol Ther* 2012;13:1269-75. Impact factor 2.64.
44. Luckett, T, Davidson, P. M, Boyle, F., Liauw, W., Agar, M., Green, A. & Lovell, M. Australian survey of current practice and guideline use in adult cancer pain assessment and management: Perspectives of oncologists. *Asia Pacific Journal of Clinical Oncology*, 2012 epub Dec 17. Impact factor 0.585
45. Hillen M, Butow P, Tattersall MNH, Hruby G, Boyle F et al. Validation of the English version of the Trust in Oncologist Scale. *Patient Education and Counseling*. 2012. Epub 6 December 2012. Impact factor 2.929
46. Jang H, Spillane A, Boyle F, Fogarty G. Radiotherapy can cause haemostasis in bleeding skin malignancies. *Case reports in Medicine*, 2012 ID 168681 epub Dec 30.

47. Winstanley J, Saw R, Boyle F, Thompson J. The FACT-Melanoma Quality of Life Instrument: Comparison of a five and four point response scale using the Rasch Measurement Model. *Melanoma Research*, 2013. 23:61-9. Impact factor 2.187.
48. Winstanley J, White E, Boyle F, Thompson J. What are the pertinent issues for melanoma cancer patients: Aiming for the development of a new module to accompany the EORTC core questionnaire. *Melanoma Research*. 2013. 23:167-74. Impact factor 2.187
49. Chung L, Shibli S, Moore K, Elder EE, Boyle FM, Marsh DJ, Baxter RC (2012) Tissue biomarkers of breast cancer and their association with conventional pathologic features. *Br J Cancer*. 2013, 108: 351-60. Impact factor 5.04
50. Goss P, Smith I, O'Shaughnessy J, Ejlersen B, Kaufmann M, Boyle F et al. Adjuvant Lapatinib for women with early stage Her2 positive breast cancer: a randomised, controlled phase 3 trial. *Lancet Oncology*, 2013, Jan 14:88-96. Impact factor 22.59
51. Metzger-Filho O, Azambuja E, Bradbury I,...Boyle F et al. Analysis of regional timelines to set up a global phase 3 clinical trial in breast cancer: the ALTTO experience. *The Oncologist*, 2013, 18:13-40. Impact Factor 3.91.
52. Butow PN, Sze M, Eisenbruch M, Bell ML, Aldridge LJ, Abdo S, Tanious M, Dong S, Iedema R, Vardy J, Hui R, Boyle F, Liauw W, Goldstein D. Should culture affect practice? A comparison of prognostic discussions in consultations with immigrant versus native-born cancer patients. *Patient Educ Couns*. 2013 Mar 28. S0738-3991. Impact factor 2.9.
53. Cusack L, Brennan M, Baber R, Boyle F. Menopausal symptoms in breast cancer survivors: Management update. *British Journal General Practice*. 2013, 63:51-2. Impact Factor 1.83.
54. Stein R, Clarke S, Boyle F, Dunn S, Sharp L. A randomised controlled trial of a structured intervention to facilitate end-of-life decision-making in patients with advanced cancer. *J Clin Oncol*, 2013, 31:3403-10. Impact Factor 18.9.
55. Thewes B, Bell M, Butow P, Beith J, Boyle F et al. Psychological morbidity and stress but not social factors influence level of fear of cancer recurrence in young women with early breast cancer: results of a cross-sectional study, *Psycho-Oncology*, 2013, 22:2797-806. Impact Factor 3.5
56. Kemp A, Preen DB, Saunders C, Boyle F, Bulsara M, Holman CD, Malacova E, Roughead EE. Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice. *PLoS One*. 2014 Jan 2;9(1):e84835.
57. McCarthy N, Boyle F, Zdenkowski N et al. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). *The Breast*. 2014, 23: 142-51.

58. Tan JD, Butow PN, Boyle FM, Saw RPM, O'Reilly A. A Qualitative Assessment of Psychosocial Impact, Coping and Adjustment in High-Risk Melanoma Patients and Caregivers. *Melanoma Research*. 2014, 24:252-60.
59. Juraskova I, Butow P, Bonner C, Bell ML, Smith AB, Seccombe M, Boyle F, Reaby L, Cuzick J, Forbes JF. Improving decision-making about clinical trial participation: A randomised controlled trial of a decision aid for women considering participation in a breast cancer prevention trial (IBIS-II). *British Journal of Cancer*. 2014, 11:1-7.
60. Gormally JF, Izard MA, Robinson BG, Boyle FM. Pituitary metastasis from breast cancer presenting as diabetes insipidus. *BMJ Case Rep*. 2014 April 12<sup>th</sup>.
61. Lovell MR, Luckett T, Boyle FM, Phillips J, Agar M, Davidson PM. Patient education, coaching and self-management for cancer pain. *Journal of Clinical Oncology*. 2014, 32:1712-20.
62. Kemp A, Preen DB, Saunders C, Boyle F, Bulsara M, Malacova E, Roughead EE. Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice? *Springer Plus* 2014; 3: 282.
63. Brennan M, Butow P, Spillane A, Boyle F. "Patient reported quality of life, unmet needs and care coordination outcomes— moving towards targeted breast cancer survivorship care planning." *APJCO*. 2014, E published Sep 22.
64. Chung L, Moore K, Phillips L, Boyle FM, Marsh DJ, Baxter RC."Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer". *Breast Cancer Research*, 2014, 16:R63:
65. de Azambuja E, Holmes A, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby R, Untch M, Jackisch C, Lang I, Smith I, Boyle F et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. *Lancet Oncol*. 2014 Sep;15(10):1137-46
66. Oh B, Butow P, Boyle F, Beale P, Costa D, Pavlakis N, Bell D, Choi SM, Lee MS, Rosenthal D, Clarke S.Effects of Qigong on Quality of Life, Fatigue, Stress, Neuropathy, and Sexual function in Women with Metastatic Breast Cancer: A feasibility Study. *International Journal of Physical Medicine & Rehabilitation*. In press –accepted July 2014
67. Bowen JM, Mayo BJ, Plews E, Bateman E, Wignall A, Stringer AM, Boyle FM, Keefe DM. Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. *Cancer Chemother Pharmacol*. 2014. 74: 617-27.
68. Butow P, Brown R, Aldridge J, Juraskova I, Zoller P, Boyle F, Wilson M, Bernhard J. Can consultation skills training change doctors' behaviour to increase involvement of patients in making decisions about standard treatment and clinical

trials: a randomized controlled trial. *Health Expect*. 2014 Jun 30. [Epub ahead of print]

69. Brennan M, Gormally JF, Butow P, Boyle F, Spillane A. "Survivorship care plans in cancer: a systematic review of care plan outcomes." *Br J Cancer*. 2014. 111:1899-908.

70. Winstanley J, Young TE, Boyle FM et al. "Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC melanoma module. *Melanoma Research*. 2015, 25:47-58.

71. Read RL, Flitcroft K, Boyle FM, Spillane AJ. "Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer". *ANZ J Surgery*. 2015, Jan 22 [epub ahead of print].

72. Van den Hurk C, Winstanley J, Young A, Boyle F. "Measurement of chemotherapy induced alopecia – time to change" *Supportive Care in Cancer*. February 10<sup>th</sup>, 2015 [epub ahead of print].

73. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, et al. Goserelin for ovarian protection during breast cancer adjuvant chemotherapy. *N Engl J Med* 2015 (In Press – Expected date of publication 5 March 2015)

74. Gelmon K, Boyle F et al. Lapatinib or trastuzumab plus taxane therapy for HER2 positive advanced breast cancer: the final results of NCIC CTG MA.31. *Journal of Clinical Oncology*. Accepted November 2014

75. Lovell M, Luckett T, Boyle F, et al. Adaptation of international guidelines on assessment and management of cancer pain for the Australian context. *Asia Pacific Journal of Clinical Oncology*. Accepted 12<sup>th</sup> January 2015.

76. Boyle F, Smith I, O'Shaughnessy J, Ejlertson B, Buzdar A, Fumoleau P, et al. Health Related Quality of Life of women in TEACH, a randomized placebo controlled adjuvant trial of lapatinib in Early Stage Human Epidermal Growth Factor Receptor (HER2) Overexpressing Breast Cancer. *European Journal of Cancer*, Accepted 17 February 2015.

77. Zdenkowski N, Butow P, Fewster C, Beckmore C, Wells K, Forbes J, Boyle F. Exploring decision making about neoadjuvant chemotherapy for breast cancer. *The Breast Journal*, Accepted February 20<sup>th</sup> 2015.

78. Brennan M, Boyle F, Butow P, Spillane A. Evaluation of a survivorship care plan: long term use, care coordination and quality of life in breast cancer survivors. *Beast Cancer Management*. Accepted February 25, 2015.



**Published Guidelines**

1. Clayton J ... Boyle F. "Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers." MJA Supplement, 2007: 186
2. Snyder R, Boyle F et al "Clinical Recommendations for the use of lapatinib ditosylate plus capecitabine for Patients with advanced or metastatic Her2 positive breast cancer." Asia Pacific Journal Clinical Oncology, 2009:5:4-16.
3. Australian Adult Cancer Pain Management Working Group. Cancer Pain Management in adults. Evidence-based Clinical Practice Guidelines adapted for use in Australia. Sydney: Cancer Council Australia. Available from: [http://wiki.cancer.org.au/australia/Guidelines:Cancer\\_pain\\_management](http://wiki.cancer.org.au/australia/Guidelines:Cancer_pain_management)
4. Cancer Australia Guidelines for the Management of CNS metastases in women with breast cancer. Cancer Australia website May 8<sup>th</sup> 2014. Chair of working group.

**Invited Reviews**

1. Boyle FM. " New anticancer drugs: out of the black hole and coming to a clinic near you." Cancer Forum, 2002, 25:149-50.
2. Baber RJ, O'Hara JL, Boyle FM, "HRT: to use or not to use." Medical Journal of Australia 2003, 178:630-633.
3. Brennan M, Spillane A, Butow P, Boyle F. "Survivorship care in breast cancer". Australian Family Physician. 2008 37:826-830.
4. Boyle F. "The Search for the Holy Grail: Evolving targeted therapies in breast cancer" Cancer Forum, 2008:32:159-163.
5. Boyle FM. "Multidisciplinary Care: Optimising Team Performance." Cancer Treat Res, 2009. 151:93-101
6. Lovell Mr, Boyle FM. "Cancer Pain Management." Medicine Today. 2010:11:33-40.
7. Brennan ME, Butow P, Marven M, Spillane AJ, Boyle FM. "Follow-up after breast cancer treatment— Views of Australian women." Australian Family Physician, 2011:40:311-6.
8. Boyle F, Winstanley J, Andrews K. Therapy update: "Scalp cooling for prevention of chemotherapy induced alopecia." Australian Doctor, November 25, 37-8. 2011
9. Cusack L, Brennan M, Boyle F. Therapy update "Managing menopausal symptoms after breast cancer treatment" Australian Doctor, June 2012.

## Letters

1. Boyle, FM. "Adverse interaction of herbal medicine with breast cancer treatment." *Med J Aust*, 1997,167:286.
2. Boyle FM, Dunn SM, Heinrich P. "More than one way to foster communication skills for medical oncology fellows: A National Programme in Australia." *JCO* 2003, 21:4225. Impact Factor 18.9
3. Juraskova I, Butow P, Lopez A, Seccombe M. Boyle F, McCarthy N, Forbes J. "Improving consent to clinical trials: successful pilot of a decision aid." *JCO*, 2007 25:1443-44. Impact Factor 18.9
4. Boyle F, Forbes J, "Breast Cancer Survivors." *Australian Family Physician*, 2008 37:791.
5. Gedye C, Boyle F. "Optimizing treatment for Australian melanoma patients could save taxpayers millions of dollars annually". *Medical Journal of Australia*, February 16<sup>th</sup>, 2015.

## Editorials

Ackland SP, Bull JM, Boyle FM. "Nab-paclitaxel: a bright new SPARC in taxane therapy of cancer" *Asia Pacific Journal Clinical Oncology*, 2009;5:147-150.

## Recent published abstracts at International meetings (papers in preparation).

1. Gelmon K, Boyle et al, First results of the MA31 Trial. Late Breaking Abstract, ASCO Chicago 2012 (oral presentation – paper accepted JCO 2014).
2. Boyle F, Smith I, O'Shaughnessy J et al. Lapatinib in Her2+ early breast cancer: Quality of Life analysis. American Society of Clinical Oncology Chicago 2012 (poster – paper submitted Lancet Oncology 2014).
3. Webber K, Girgis A, Bennett B, Bonaventura A, Boyle F et al. The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners. American Society of Clinical Oncology Chicago 2013 (poster).
4. Piccart M ....Boyle F.... First Results of the phase III ALTTO trial comparing one year of anti her2 therapy with lapatinib alone, trastuzumab alone, their sequence or their combination in the adjuvant treatment of Her2 positive early breast cancer. American Society of Clinical Oncology, 2014, Plenary oral presentation.
5. Moore H...Boyle F et al. Prevention of Early Menopause (POEMS) study. American Society of Clinical Oncology, 2014, Breast Cancer Oral Presentation. (Accepted for publication NEJM 2014).
6. Dueck A, Hillman D, ...Boyle F et al. Quality of Life among patients with Her2 + breast cancer treated with adjuvant lapatinib and trastuzumab in the ALTTO study. American Society of Clinical Oncology 2014, Poster presentation.
7. Parulekar W...Boyle F et al. Lapatinib or trastuzumab with taxane therapy as first-line treatment in metastatic Her2 positive breast cancer: A biomarker analysis in NCIC CTG MA31. American Society of Clinical Oncology 2014, Poster presentation.

8. Phillips K-A, .... Boyle F et al Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT). San Antonio Breast Cancer Symposium 2014 Poster Presentation.
9. Liu MC, ... Boyle F, et al. Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial. San Antonio Breast Cancer Symposium 2014 Poster Presentation
10. Zdenkowski N, Butow P...Boyle F. Neoadjuvant systemic therapy for breast cancer: A survey of ANZ specialists. St Gallen Breast Cancer Symposium 2015 Vienna.

### **Book Chapters**

1. Boyle FM, Grossman SC. "Pain Management" in "Oncologic Therapies", Ed Volkes EE and Golomb HM, Springer, Chicago, 1999.
2. Lovell MR, Boyle FM. "Optimising cancer pain control" in "Handbook of communication in Oncology and Palliative Care." Kissane DW, Bultz BD, Butow PN, Finlay I (Eds) Oxford University Press, Oxford. 2010. ISBN 978-0-19-923836-1
3. Blyth FM, Boyle FM. "Cancer Pain" in "Chronic pain epidemiology: from aetiology to public health", Croft P, Blyth F, van der Windt D, Oxford University Press, 2011. ISBN 9780199235766

### **National Reports**

1. Marlin A, Redman S, Clarke C, Clark C, Boyle F. "Breast Cancer research in Australia: current research and future priorities" NHMRC National Breast Cancer Centre, 1997.
2. Browning, Thomas and Assoc, Redman S, Pillar C, Turner J, Boyle F. "Lymphoedema: prevalence, risk factors and management: a review of research. NHMRC National Breast Cancer Centre, 1998.

### **National Evidence Based Guidelines**

1. NHMRC Clinical Practice Guidelines for the Management of Acute Pain. 1999.
2. NHMRC Psychosocial Clinical Practice Guidelines - information , support and counseling for women with breast cancer. 2000.
3. NHMRC Clinical Practice Guidelines for the Management of Advanced Breast Cancer. 2001, and NHMRC Consumer Guidelines for women with metastatic breast cancer. 2001.
4. NHMRC Clinical Practice Guidelines for the Management of Early Breast Cancer. 2002 and NHMRC Consumer Guidelines for women with early breast cancer, 2003.

5. NBCC Recommendations for Aromatase Inhibitors as Adjuvant Endocrine therapy for post-menopausal women with hormone receptor positive breast cancer, 2006.
6. Australian Cancer Network Adult Brain Tumour Working Party. Clinical Practice Guidelines for the management of adult gliomas. Cancer Council Australia, 2009.
7. Cancer Australia Guidelines for the management of brain metastases from breast cancer 2013/14. Committee Chair.
8. Australian Adult Cancer Pain Management Guidelines 2013 Cancer Council Australia. Citation above.

**Awards**

- 1992 Royal Australasian College of Physicians, NSW Advanced Trainee research award.
- 1995 Beryl and Jack Jacobs Research Award, Royal North Shore Hospital.
- 1995 Multinational Assoc for Supportive Care in Cancer, Young Investigators Award.
- 1996 Medical Oncology Group of Australia, Travel Award.
- 1996 American Association for Cancer Research, Young Investigators Award.
- 1997 RNSH Medical Staff Council, Travel Award (for post-doctoral research at Johns Hopkins Oncology Center).
- 1997 NSW Cancer Council, Professional Education and Training Grant (for Post doctoral research at Johns Hopkins Oncology Center).
- 1999 Medical Oncology Group of Australia, Travel Award (for presentation at Society of Neurooncology Meeting, Arizona).
- 2002 Australian Medical Association Women's Health Award for services to breast cancer research, advocacy and policy.
- 2008 Australia Day Honours: Member of the Order of Australia as a clinician and cancer researcher, particularly in the areas of breast and brain cancer treatment, and as a contributor to medical education and professional organizations.
- 2008 Awarded "Woman of Achievement". Hornsby-Kuringai Zonta Club
- 2009 Highly Commended: Astra Zeneca / NBCF Breast Cancer Care Award
- 2009 Australian Cancer Network Distinguished Service Award for Development of the Glioma guidelines.
- 2011 Palms Excellence in Teaching Award, Northern Clinical School for sustained excellence in medical student teaching
- 2012 Sydney Medical School Excellence in Teaching award for Pam McLean Centre for communication skills teaching.
- 2013 Sydney University Vice Chancellor's Award for outstanding support of the student experience for Pam McLean Centre.
- 2013 Medical Oncology Group of Australia / Novartis Cancer Achievement Award

**Recent Invited presentations at International Meetings.**

2008 International Breast Cancer Study Group ASM, Budapest, Hungary.  
“Improving communication in breast cancer research teams”

2008 Phillipines Society for Medical Oncology ASM  
“Targeted therapies in metastatic breast cancer”  
“Update on adjuvant therapy in breast cancer”

2008 American Society of Clinical Oncology, Chicago. Breast Cancer Survivorship  
Poster Discussant: Breast Cancer Supportive Care

2008 New Zealand Psycho-Oncology ASM  
“Discussing prognosis: I do have a crystal ball”  
“Improving communication in cancer teams”

2009 Asian Oncology Summit, Singapore 2009  
“Breast Cancer Survivorship”

2009 Massachusetts General Hospital Breast Cancer Rounds.  
“New approaches to clinical trial consent”

2010 International Society of Melanoma Centres, Sydney  
“Advanced Melanoma – systemic and supportive therapy”  
“Psychosocial support systems in melanoma centres”

2011 New Zealand Breast Cancer Nurses Annual Meeting  
“Dealing with emotional reactions”  
“Improving team communication”

2012 Sydney International Breast Cancer Symposium  
“Neoadjuvant clinical trials in breast cancer: New Directions”

2012 International Psycho-oncology Society ASM Brisbane  
“Discussing end of life issues” Workshop

2014 New Zealand Breast Cancer Nurses Annual Meeting  
Communication in cancer teams  
Cancer Pain Management Guidelines

**Recent Invited Presentations at National Meetings.**

2008 ANZ Breast Cancer Trials Group ASM, Wellington NZ.  
“Skin Deep: toxicity of targeted therapies”

2008 General Surgeons Australia ASM, Coolum.  
“Medicolegal implications of multidisciplinary care”  
“Enhancing teamwork in cancer”

2008 Leura Breast Cancer Meeting, Sydney.

“Targeted therapies in early breast cancer: the search for the Holy Grail”

2009 Womens’ Health Conference, Gold Coast

“Breast Cancer – Medical Oncology update”

“Communication with the team in breast cancer management”

2009 Breast Nurses Interest Group, CNSA meeting, Newcastle.

“Breast Cancer Survivorship issues”

2009 MOGA / Best of ASCO, Canberra.

“Breast Cancer update”

2009 COSA ASM Gold Coast

“Improving the patient experience of chemotherapy.”

2010 ANZ Breast Cancer Trials Group ASM Sydney

“Is it still appropriate to test new therapies in advanced breast cancer?”

2010 MOGA/ Best of ASCO, Sydney

“Breast Cancer update”

2010 COSA ASM Melbourne

“Meeting the needs of women with Advanced Breast Cancer”

2011 Breast 2011 (Radiology) Sydney

“Advances in Breast Cancer Treatment – surgical and oncological.”

2011 Australian Association of Clinical Biochemists ASM Sydney

“Tailoring breast cancer therapy – so near and yet so far.”

2012 COSA ASM Brisbane

“The grey zone – intermediate risk breast cancer”

“Melanoma Quality of Life issues”

2013 ASM of ANZUP

“Clinical Trials consent”

“Getting consumers off the bench”

2013 ASM of ANZ Breast Cancer Trials Group

“Recent IBCSG trial results”

2013 ASM of COSA Debate “The older we are, the less we get”

2014 ASM of ANZ Breast Cancer Trials Group

Consent for Neoadjuvant trials.

Altto results update

2014 ASM of Medical Oncology Group of Australia

Her 2 positive breast cancer: One lump or two.

Implementation of Scalp Cooling in the Australian context (Poster)

2014 ASM of Clinical Oncology Society of Australia and World Cancer Conference.

Plenary Session: Communicating about high cost therapies.

Breakfast Session: Scalp Cooling implementation for prevention of CIA

Oral Presentation Best of the Best: “Half of women with early breast cancer stop endocrine therapy before five years: results from an Australian population-based study”

## **Teaching and University Service:**

### **1. Medical Student Teaching:**

I am responsible for coordinating undergraduate teaching in Oncology for the Northern Clinical School of the University of Sydney. This involves

- Curriculum development, including a new module on taking a spiritual history in 2011-14
- Coordinating the oncology block in stage 2 at the Northern Clinical School for over 10 years, developing timetables and briefing faculty, updating material each year including PBL cases and lectures.
- Lecturing in the oncology block each year (5-6 per year) and running PBL feedback sessions weekly (4 per block)
- Supervising clinical placements in oncology at the Mater during years 3 and 4,
- Writing exam questions, long case clinical examining annually
- Supervising medical students undertaking honours projects (8 since 1999).
- Developing and implementing a clinical reasoning session for Stage 3 students on Cancer of Unknown primary. An interactive feedback session after the CRE was highly successful at Northern in 2011.
- A session on Symptom Control in Cancer for Stage 3 students is co-facilitated with Dr Melanie Lovell, including case and evidence based material.

In 2012 I was awarded the PALMS Excellence in teaching award for sustained contributions to teaching in the Oncology Block at Northern.

### **2. Pam McLean Cancer Communications Centre: Medical Director**

After initial training in facilitation by Lesley Fallowfield and the National Breast Cancer Centre in 1997, I became clinical consultant to the Australian Health Communications Centre, Northern Clinical School, and was trained by Prof Stewart Dunn and Dr Paul Heinrich in the development (including curriculum development, script writing and training of actors) and facilitation of interactional skills workshops for cancer professionals.

- In 2001, the Unit was reformed as the Pam McLean Cancer Communications Centre, and I was appointed Medical Director. This collaborative work involves research and teaching in medical communication, and developing local, national and international programs for a wide range of health professionals.



- Current partners include the National Breast and Ovarian Cancer Centre, the American Society for Clinical Oncology, the NSW Cancer Institute, the Medical Oncology Group of Australia and RACP, the Clinical Oncological Society of Australia, the Cancer Society of New Zealand, ANZ BCTG and TROG, and the Melanoma Institute of Australia and researchers from POCOG and CEMPED and other University of Sydney initiatives.
- In 2012 the Pam McLean Centre was awarded the Sydney Medical School excellence in teaching award and in 2013 Sydney University Vice Chancellors' award for outstanding contribution to the student experience.
- Current Workshops focus on the areas of
  - Breaking Bad News and managing emotional reactions (dealing with bad news)
  - Clinical Trials Consent, including tailored workshops for new trials
  - Transition to Palliative Care / End of Life Issues
  - Communicating with young women with breast cancer
  - Discussing Prognosis in early and advanced cancer
  - Open Disclosure of Adverse Events
  - Communicating in the Multidisciplinary Team
  - Managing Cancer Pain
  - Preparing patients for procedures
  - Discussing high cost therapies and complementary therapies
  - Preventing Professional Burnout
- Recently I have gained additional experience in making educational film, DVD and interactive web based modules, which allows wider dissemination of our work.

### **3. *Masters Programmes***

Current Lecture (interactive) on Clinical Trials Consent in the Masters of Health Psychology Programme 2011-14. Feedback was very good to excellent.

Previously I have contributed to the Masters of Pain Management (Cancer Pain Module Development and facilitation) (2001-6) and Reproductive Health (Hormones and Breast Cancer Lecture) (2001-6).

### **4. *Postgraduate research student supervision.***

I have supervised 2 completed PhD and 2 Masters students

- Susan Murphy (Awarded 2007), "Studies of Thalidomide-cytotoxic interactions in 9L gliosarcoma in rats." Susan now works in the USA.
- Melanie Lovell (Awarded 2009): "Cancer pain education for patients." This work led to a national resource published by the Cancer Council.
- Masters of Surgery Sabah Shibli (Awarded 2013) "The Use of Proteomics to Identify Proteins in Breast Tissue as Diagnostic Biomarkers." Kolling Institute with Robert Baxter and Katrina Moore.

- Jason Tan Masters of Clinical Psychology (Awarded 2013)  
“Psychosocial and support needs of patients with stage 3 melanoma”  
with Phyllis Butow and Robyn Saw.

Current Student supervision includes

- Meagan Brennan PhD (submission 2014) “Survivorship care planning in breast cancer.” Patricia Ritchie Centre with Phyllis Butow, and BCNA collaborators.
- Nicholas Zdenkowski (commencing part time 2014). Decision making in Neoadjuvant chemotherapy in breast cancer. With Phyllis Butow and ANZ Breast Cancer Trials Group.

I assisted on the research team with Rhea Stein’s PhD in Psychology project on end of life care, providing patients and a scholarship from the Mater. This work has been accepted for publication in JCO, and led to a booklet used in clinical care of patients at the Mater.

### **National Professional Service.**

#### **1. NHMRC National Breast and Ovarian Cancer Centre / Cancer Australia**

Senior Clinical Advisor in Medical Oncology 1997-2003

Expert Advisor in Medical Oncology, 2004-2006

Member, Board of Directors 2006-2009

Member, Guidelines Steering Group 2011-present

I have been involved in many NBCC / NBOCC projects and working parties:

- Development and implementation of Evidence Based Guidelines
- Communication skills module development and implementation
- Review of the evidence for management of lymphoedema (1997).
- Review of the evidence High Dose Chemotherapy in Breast Cancer (2000).
- Co-Chief Investigator on a Randomised trial of a hospital detailing kit for the implementation of early breast cancer guidelines (funded by NHMRC)
- Chairing Medical Oncology Expert Advisory Group 1997-01
- Development of an educational kit for health professionals in regional and remote areas in the management of adjuvant therapy for early breast cancer (RHSET Grant)
- Policy development and strategic planning through my role on the Board
- Since the amalgamation of the NBOCC with Cancer Australia, I have been invited to join the Communication and Information Advisory Group, and to chair the working group overseeing the development of the Guidelines for the Management of Brain Metastases in Breast Cancer
- Media Comment and fund raising activities to represent the views of the NBOCC

#### **2. Breast Cancer Network of Australia**

**BCNA is the national peak body representing people affected by breast cancer.**

Board member 2006 - 2013

- Regular contributor to “The Beacon” and public forums
- Advocacy collaborations since 2000 eg drug access policy
- Involvement in National Consumer meetings 2000, 2004, 2006, 2009, 2011, 2013 as a speaker and advisor to the organising committees.
- Speaker at 2012 “Strength to Strength” Conference at Sydney international breast cancer symposium.
- Assisted in the development of the “My Journey” kit for women with early breast cancer, and a similar resource for women with advanced breast cancer launched in 2007 “Hope and Hurdles” and recently updated.
- Research collaborations around high cost drugs, survivorship care and neoadjuvant chemotherapy.
- Presenting updates on research and care at community forums for women with breast cancer funded by the Australian Government, in regional NSW and Victoria during 2010-14.
- Media comment and appearances to support advocacy and fund raising activities of the group

### ***3. ANZ Breast Cancer Trials Group***

**The ANZBCTG has led clinical trial activity in breast cancer for 30 years, in collaboration with similar academic groups around the world.**

- Involvement in recruiting patients to group trials since 2000
- Elected to Board of Directors in 2001 – elected Chair in July 2012
- Chaired Scientific Advisory Committee in 2005-10 directing research programme and interfacing with international groups
- Convenor, Annual Scientific Meetings 2008 Wellington NZ, and 2009 Darwin and Sydney and Melbourne (with COSA) 2010, Gold Coast 2011, Hobart 2012.
- PI on 8 NHMRC project grants with responsibility for over 2000 patients currently on study
- PI on NSW Cancer Institute / Cancer Australia Infrastructure Grants involving our trials programme 2006-9 and 10-12
- Representing the Group on International Advisory Councils for BIG and IBCSG, planning international clinical trials activity in collaboration with North American Intergroup 2010-13.
- Media comment and public appearances to publicise and clarify results of trials relevant to the Australian Community and to support the fund raising activities of the group.

### ***4. Medical Oncology Group of Australia***

- Member since 1992
- Advanced Trainee Representative 1993 on Executive and SAC
- Annual Scientific Meeting Organising Committees 1994, 1998, 1999, 2001
- Executive Committee Member 1997-2000
- Chairman of the Executive 2001-2, representing the Group to the RACP and Government and the community
- Specialist Advisory Committee supervising Training 2001-2 Chair
- Medical Oncology Representative on Haematology JSAC and Palliative Medicine Chapter SAC 2001-2

- Current member of Education and Drug Issues Subcommittees and Breast Interest Group Chair
- Convenor, National communication skills programme 2001 -2014
- Represented MOGA at the Senate Enquiry into Palliative Care in Australia 2012

#### ***5. Royal Australasian College of Physicians***

- Fellow since 1992
- Chair, Specialist Advisory Committee in Medical Oncology
- Current IRT participant and supervision skills facilitator
- Convenor, Medical oncology Curriculum for advanced training working group

#### ***6. Clinical Oncological Association of Australia:***

- Member since 1990
- Council Member 2001-2 representing MOGA and 2012- representing ANZBCTG
- Clinical Trials Infrastructure grant management group 2008-2010
- Annual Scientific Meeting Organising Committee Melbourne 2010

### **INTERNATIONAL PROFESSIONAL SERVICE**

#### ***1.American Society for Clinical Oncology:***

- Member since 2001, regular attendee at meeting
- Participant, inaugural communication skills workshop New Orleans 2004
- Communication skills joint workshop convenor with COSA 2005
- Meet the Professor Session at ASCO Meeting Atlanta New Orleans
- Poster Discussant 2010
- Best of ASCO presenter 2010 Canberra, 2011 Sydney

#### ***2.International Breast Cancer Study Group***

- Scientific Advisory Committee Member since 2010
- Council Member commencing in 2015

#### ***5.The Breast (Journal) Editorial Advisory Board*** Appointed 2012-13

#### ***8.Reviewer for International Journals***

- Psycho-oncology
- Supportive Care in Cancer
- Palliative Medicine
- Journal of Clinical Oncology
- Asia Pacific Journal of Clinical Oncology

#### ***9.Executive Committee Member for International Breast Cancer Clinical Trials*** – this involves quarterly meetings and additional communication to plan, manage, analyse and report results.

- **ALTTO** adjuvant lapatinib and trastuzumab optimization (BIG)
- **TEACH** delayed adjuvant lapatinib (Massachusetts General Hospital and GSK)
- **COMPLETE** first line metastatic breast cancer lapatinib vs trastuzumab (MA31, National Cancer Institute of Canada)
- **Communication in Clinical Trial Consent Training Study** IBCSG

**LOCAL PROFESSIONAL SERVICE**

- **Chair, Department of Cancer Medicine, Mater Hospital** 2004-present
  - Representing the Department on the Medical Advisory Committee
  - Managing strategic planning, building works, MDT functioning, staffing, morbidity and mortality review, accreditation and service improvement.
  - Supervision of interns commencing in 2015
- **Medical Advisory Committee and Appointments and Credentialling Committee, Mater Hospital**
  - Chair 2007-2009, representing the medical staff at Hospital Board level
  - Departmental Representative 2004-present, quarterly meetings
  - Secretary, Mater Medical Staff Association 2012-13
- **Northern Sydney Breast Group** – member since 2007, Annual meeting convenor 2012, speaker each year on clinical trials portfolio.
- **Breast Cancer Support Service Mater** - Breast Cancer Education and Support Group lecturer 4 times per year 2001-12
- **Soiree NSW Cancer Council** – young women’s breast cancer support group lecturer annually since 2007
- **Encore** Exercise after breast cancer – lecturer in training programme for facilitators annually since 2007
- **Qantas Cabin Crew Cancer Support Group** – facilitator and lecturer since 2008
- **Basic Sciences of Oncology** – lecturer annually on breast cancer and mitotic inhibitors for medical oncology trainees from NSW
- **Cancer Council NSW Relay for Life** Patron and guest speaker 2010
- **Spirituality in Health Care** – speaker at Spirituality in the Pub, Kincoppal-Rose Bay School and St Clare’s Waverley community forums 2011-12, Radio National.
- **NSW Medical Oncology Trainees Education meetings** 2013 Pregnancy, Fertility and breast cancer and Advanced Breast Cancer Chemotherapy/ 2014 high cost drugs communication
- **Lymphoedema Association of ANZ Annual Meeting** 2013 Chemotherapy for breast cancer and its impact on oedema.
- **Cancer Institute NSW EVIQ protocol review committee**  
Breast Cancer and Melanoma protocol updates 2013-14
- **Cancer Institute NSW clinical research leaders committee**  
2013-14 participant representing Mater
- **Cancer Institute NSW implementation advisory group**  
2013-14 participant representation Northern TRU